|
ROTH Capital Partners Completes
$3.9 Million Registered Direct
Offering for PharmAthene, Inc. |
|
|
|
|
|
Transaction Information
On July 23, 2010, PharmAthene closed a
$3.9M registered direct offering of 2,785,714 newly issued shares of its common
stock at $1.40 per share and warrants to purchase an aggregate of 1,323,214
shares of its common stock at an exercise price of $1.63 per share, the closing
price of PharmAthene's common stock on July 19, 2010. The warrants will be
exercisable beginning on January 23, 2011 and will expire on January 23, 2017.
Roth Capital Partners, LLC served as sole placement agent for the offering.
|
|
Client Information
PharmAthene, Inc. (AMEX:PIP)
("PharmAthene" or the "Company") was formed to meet the critical needs of the
United States and its allies by developing and commercializing medical
countermeasures against biological and chemical weapons. PharmAthene's lead
product development programs include:
-
SparVaxTM - a second
generation recombinant protective antigen (rPA) anthrax vaccine
-
Valortim® - a fully human
monoclonal antibody for the prevention and treatment of anthrax infection
-
Protexia® - a novel bioscavenger for the prevention and treatment of morbidity and mortality
associated with exposure to chemical nerve agents
ROTH Capital Partners
Roth
Capital Partners, LLC (ROTH), is a relationship-driven full service investment
bank focused on identifying opportunities for institutional investors in
U.S.-listed equity securities of companies based in the U.S. and China.
Headquartered in Newport Beach, CA, with offices throughout the U.S. and a
Shanghai Representative Office, the employee-owned firm provides analytical
research, trading, capital raising, and business combination advisory services.
ROTH seeks to implement innovative financing strategies to efficiently meet the
liquidity and valuation requirements of both its corporate and institutional
investor clients.
|
|
|
|
The material,
information and facts discussed in this announcement other than the information
regarding ROTH Capital Partners, LLC (“ROTH”) and its affiliates, are from
sources believed to be reliable, but are in no way guaranteed to be complete or
accurate. This announcement should not be used as a complete analysis of any
companies, securities or topics discussed herein. Additional information is
available upon request. This is not, however, an offer or solicitation of the
securities discussed. Any opinions or estimates in this announcement are subject
to change without notice. An investment in any security based on this
announcement may involve risks and uncertainties that could cause actual results
to differ materially from the forward-looking statements. Additionally, such
investments may involve a high degree of risk and may not be suitable for all
investors. No part of this announcement may be reproduced in any form without
the express written permission of ROTH. Copyright 2010. |
ROTH Capital Partners
24 Corporate Plaza
Newport Beach, California 92660
US
Read the VerticalResponse marketing policy.
|
|
| | | |